Newsgroup: it.economia.borsa
Titolo: Cell therapeutics news

Data from XYOTAX(TM) STELLAR Trials Presented at 2006 Meeting of American
Society of Clinical Oncology
Sunday June 4, 8:30 am ET
Gender-Specific Survival Benefit Reported in Women Treated with XYOTAX
ATLANTA, June 4 /PRNewswire-FirstCall/ -- At the 2006 Annual Meeting of the
American Society of Clinical Oncology (ASCO), data from Cell Therapeutics,
Inc.'s (CTI) (Nasdaq: CTIC; MTAX) phase III STELLAR trials of XYOTAX(TM)
(paclitaxel poliglumex) in patients with non-small cell lung cancer (NSCLC)
were presented.
Effect of Gender on Outcome in the STELLAR 3 and 4 Trials (Abstract #7039)
In a poster discussion presentation Helen Ross, M.D., Medical Oncologist at
the Oregon Clinic and Director of Lung Cancer Research at the Earle A.
Chiles Research Institute in Portland, Oregon, presented a composite
analysis of the STELLAR 3 and 4 studies, which demonstrated that XYOTAX had
a significant impact on survival in women compared to those on the control
arms, while men had similar survival in both arms of the studies. In
addition, in women younger than 55 years old, overall survival was prolonged
for patients on the XYOTAX arm compared to the control arm (HR: 0.51,
p=0.03), whereas in women 55 years and older, overall survival was similar
between treatment groups (HR: 0.75, p=0.134). In STELLAR 3, estrogen levels
were available for the majority (92 percent) of women on the trial. Patients
with pre-menopausal estrogen levels (serum estrogen >30 pg/mL), regardless
of age, had a significant improvement in survival when treated with XYOTAX
in combination with carboplatin compared to patients treated with paclitaxel
plus carboplatin (HR: 0.54, p=0.039), but survival was similar between the
two arms of the study in patients with post-menopausal estrogen levels (HR:
1.20, p=0.676).
"Most women think that breast cancer is more of a threat than lung cancer,
but more women are expected to die from lung cancer than from breast,
ovarian, uterine and cervical cancers combined. It is a serious health
crisis that most women are unaware of," said Dr. Ross.
"This presentation highlights the importance of gender and genetics on the
differential response to treatment for lung cancer. Lung cancer in women is
often diagnosed late, making it much more difficult to treat. More awareness
of lung cancer and factors such as estrogen that might explain the impact on
outcome is needed," Ross concluded.
    Table 1. Comparison of survival (days) in pre- and post-menopausal women
                       MEDIAN
                  OVERALL SURVIVAL                   1-YEAR SURVIVAL
                   XYOTAX Control    HR     pP-value XYOTAX  Control
    Pre-menopausal
    STELLAR 3       239     167     0.66     0.011     38%     22%
    STELLAR 4        NE     188     0.38     0.146     51%     16%
    Composite       309     181     0.56     0.008     43%     19%
    Post-menopausal
    STELLAR 3        NE     347     0.71     0.523     50%     36%
    STELLAR 4       320     163     0.47     0.312     40%     17%
    Composite       320     263     0.62     0.256     47%     30%
Analysis of Prognostic Factors using Cox Regression Analysis in the STELLAR
3 and 4 Trials (Abstract #7113)
In a poster presentation Mary O'Brien, M.D., Consultant Medical Oncologist
at The Royal Marsden Hospital in London, presented an analysis of prognostic
factors using Cox regression analysis. O'Brien concluded that weight loss,
presence of extra-thoracic metastasis, low LCS (lung cancer symptom) scores,
and high LDH (lactate dehydrogenase -- a tumor marker) were significant
negative prognostic factors for PS2 (ECOG performance status 2) patients
with NSCLC. Significant differences in survival based on geographic region
seen in STELLAR 3 highlighted the importance of stratification by region.
Subgroup analysis by randomization strata showed no difference in survival
between treatment arms, however trends toward improved survival for women
receiving XYOTAX were observed in STELLAR 3 and 4.
Analysis of Prognostic Factors using Cox Regression Analysis in the STELLAR
2 Trial (Abstract #7040)
In a poster discussion presentation Philip D. Bonomi, M.D., Director of
Medical Oncology, Rush-Presbyterian-St. Luke's Medical Center in Chicago,
presented an analysis of prognostic factors using Cox regression analysis.
Both overall survival and response were similar between the treatment arms.
Patients in the XYOTAX arm had significantly less anemia, neutropenia,
febrile neutropenia, infection, hair loss, fatigue, mucositis, and
gastrointestinal and respiratory symptoms, and a reduced requirement for
supportive measures to manage the effects of myelosuppression. Overall,
grade 3 neurotoxicity was significantly increased in the XYOTAX arm;
however, in patients receiving XYOTAX at a dose of 175 mg/m2, grade 3
neuropathy was equivalent to the control.
Bonomi concluded that the prognostic factors for this group of second-line
patients were virtually identical to those seen in chemo-naive NSCLC
patients, reported by O'Brien (above). In addition, shorter interval from
previous chemotherapy was also an important negative prognostic factor and
it was recommended that in the future the interval from previous systemic
chemotherapy be described in phase II trials and included as a
stratification factor in phase III studies.
For more information about this presentation, please visit our website at
http://www.cticseattle.com/investors_news-updates.htm
About the STELLAR Trials
The STELLAR trials are among the largest randomized, phase III trials to
date in either second-line non-small cell lung cancer (NSCLC) or first-line
PS2 NSCLC patients. STELLAR 2 tested XYOTAX versus docetaxel for the
potential second-line treatment of NSCLC patients. STELLAR 3 tested
carboplatin in combination with either XYOTAX or paclitaxel for the
potential first-line treatment of poor performance status (PS2) patients
with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine
for the potential first-line treatment of poor performance status (PS2)
patients with NSCLC.
About XYOTAX
XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced
chemotherapeutic that links paclitaxel, the active ingredient in TaxolŽ, to
a biodegradable polyglutamate polymer, which results in a new chemical
entity. When bound to the polymer, the chemotherapy is rendered inactive,
potentially sparing normal tissue's exposure to high levels of unbound,
active chemotherapy and its associated toxicities. Blood vessels in tumor
tissue, unlike blood vessels in normal tissue, are porous to molecules like
polyglutamate. Once inside the tumor cell, enzymes metabolize the protein
polymer, releasing the paclitaxel chemotherapy. Based on preclinical
studies, it appears that XYOTAX is preferentially distributed to tumors due
to their leaky blood vessels and trapped in the tumor bed allowing
significantly more of the dose of chemotherapy to localize in the tumor than
with standard paclitaxel. Preclinical and clinical studies support that
XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which
could lead to enhanced release of paclitaxel and efficacy in women with lung
cancer compared to standard therapies.

 chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to


 ha scritto nel messaggio 
news:1149435357....@u72g2000cwu.googlegroups.com...
sto Xiotax ha rotte le palle, è già scontato quel poco che forse
varrà
servono buone nuove sul Pix
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
son convinto che lunedi il titolo andrà alla grande!!! :) 

Arrgianf ha scritto:

analisi tecnica o insider trading?

 ha scritto nel messaggio 
news:1149438188.7...@y43g2000cwc.googlegroups.com...
Arrgianf ha scritto:

che?? non so neanche cosa significano questi 2 termini....
io credo che vada alle stelle, perchè nei giorni precedenti a questa 
assemblea il titolo è andato molto forte, e questa notizia è positiva per 
l'azienda... quindi credo che + del 2% ci andrà lunedi!
Che ne pensi? 

 Che ne pensi? 
Che se scrivi su ieb e non conosci quei due termini faresti meglio a 
lurkare per un po'.
Ciao ... Dino

"ginopilotino" <gi...@pilotino.invalid> ha scritto nel messaggio 
news:448312f4$0$14792$4faf...@reader4.news.tin.it...

:) be... se son qui, significa che aspetto che qualcuno spieghi i 2 termini 
:) va be che il primo lo so... cmq io ho detto la mia... sta domani vedere 
se ci ho azzeccato o no:) 

"ginopilotino" <gi...@pilotino.invalid> ha scritto nel messaggio 
news:448312f4$0$14792$4faf...@reader4.news.tin.it...

http://it.wikipedia.org/wiki/Insider_trading
 facevi prima a mettere questo 
link... forse eri piu' gentile :) 

+ del 2 %, ho indovinato!! :)
"Arrgianf" <esarrab...@tin.ittt> ha scritto nel messaggio 
news:44831762$0$29728$4faf...@reader2.news.tin.it...


spunto speculativo
http://www.cticseattle.com/investors_news.htm
In preclinical models, the polyglutamate technology appears to be
capable of delivering more chemotherapy directly to the tumor, making
each dose potentially more effective without increasing side effects.

 ha scritto nel messaggio 
news:1149509023.6...@i39g2000cwa.googlegroups.com...


mi ricordi uno che metteva sulla schedina tutte "X"
gli chiesi quale era la logica
"intanto si parte tutti dallo 0-0..."
ogni domenica fino alle 15.30 era milionario
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
Arrgianf ha scritto:


 e allora? non č sempre 2 %?


 acquistare il titolo e rivenderlo? Ehm... spiegami :)
Avresti dovuto acquistarlo venerdì visto che, se ricordo bene (e ora
non posso controllare), stamattina ha aperto direttamente con un
+6%.... Se avessi acquistato invece stamattina sull'onda della notizia
ora saresti a -4% invece che +2%.... :-)

+ del 2 %, ho indovinato!! :)
http://wiki.news.nic.it/QuotarBene#head-15ee27331be5f87be5fe5ff100936aced3e9de0f
 

"Skytrader"
http://wiki.news.nic.it/QuotarBene#head-15ee27331be5f87be5fe5ff100936aced3e9de0f
 

 acquistare il titolo e rivenderlo? Ehm... spiegami :)
Avresti dovuto acquistarlo venerdě visto che, se ricordo bene (e ora
non posso controllare), stamattina ha aperto direttamente con un
+6%.... Se avessi acquistato invece stamattina sull'onda della notizia
ora saresti a -4% invece che +2%.... :-)
ahhh capito :) avevo detto che lunedi avrebbe migliorato di piů del 2% 
rispetto a venerdi.
Capito... quindi č giusto come pensavo... cioč... il titolo venerdi č 
terminato con una valutazione e dopo quella notizia, ero sicuro che oggi 
guadagnava rispetto a venerdi. ok? Grazie per avermi risposto :) 

non ho tempo di quotare a mercati aperti
Skytrader:
99% Skytrading
0% Quoting
1% RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR

 ha scritto nel messaggio 
news:1149513066....@h76g2000cwa.googlegroups.com...

si si infatti ti appoggio... diciamo che è un msg Chat. scambio di opinioni 
tra noi (cosi per capirci qualcosa io) :) quinid facciamo prima a leggere 
sopra... il riferimento alla discussione si sa :) Ciao skytrader :)